Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Classical hematology 1CNS 1

Conditions

Leukemia, Myeloid, Acute 167Leukemia 86Precursor Cell Lymphoblastic Leukemia-Lymphoma 71Lymphoma 51Myelodysplastic Syndromes 38Congenital Abnormalities 32Burkitt Lymphoma 29Lymphoma, Non-Hodgkin 27Recurrence 26Leukemia, Myelomonocytic, Acute 26Leukemia, Monocytic, Acute 26Lymphoma, Mantle-Cell 23Leukemia, Erythroblastic, Acute 23Leukemia, Megakaryoblastic, Acute 21Hodgkin Disease 18Lymphoma, Large B-Cell, Diffuse 17Lymphoma, Follicular 13Myeloproliferative Disorders 12Leukemia, Myelomonocytic, Chronic 11Leukemia, Biphenotypic, Acute 11Leukemia, Eosinophilic, Acute 9Blast Crisis 9Lymphoma, B-Cell 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Anemia, Refractory, with Excess of Blasts 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms 7Multiple Myeloma 7Leukemia, Basophilic, Acute 7Leukemia, Lymphocytic, Chronic, B-Cell 6

Interventions

Radiotherapy 2Pyridoxine 2Etoposide 2Cytarabine 2Cyclophosphamide 2sodium thiosulfate 1pegfilgrastim 1pegaspargase 1etoposide phosphate 1Vincristine 1Triptorelin Pamoate 1Rituximab 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Leucovorin 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Doxorubicin 1Dexrazoxane 1Dexamethasone 1Celecoxib 1Carboplatin 1Capecitabine 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Drug-Related Side Effects and Adverse Reactions × Cytarabine × Clear all
NCT00400946 2026-02-13

05-001: Treatment of Acute Lymphoblastic Leukemia in Children

Dana-Farber Cancer Institute

Phase 3 Completed
800 enrolled 22 charts
LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Drug-Related Side Effects and Adverse Reactions

NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡